Lenalidomide Olpha (Lenalidomide)

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders.

• Multiple myeloma: improves progression‑free survival and overall response rates in adult patients.
• Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission.
• Mantle cell lymphoma: provides disease control in relapsed or refractory cases.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). This results in modulation of cytokine production, enhanced T‑cell and NK‑cell mediated immunity, and inhibition of angiogenesis, collectively contributing to its anti‑tumor activity. Additionally, it interferes with the tumor microenvironment by reducing pro‑survival signaling.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count increasing infection risk.
• Thrombocytopenia: low platelet levels leading to bleeding tendency.
• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require hydration.
• Rash: mild skin eruptions.
• Nausea: upset stomach and possible vomiting.
• Constipation: difficulty passing stool.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Secondary primary malignancies: emergence of new cancers.
• Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatotoxicity: significant liver enzyme elevation or liver injury.

When prescribing Lenalidomide, clinicians should observe several precautions to minimize risks and ensure safe use.

• Pregnancy contraindication: drug is category X and must not be used during pregnancy; effective contraception is required.
• Thromboembolic risk: assess need for prophylactic anticoagulation in patients with additional risk factors.
• Renal impairment: adjust monitoring and consider dose modification in patients with reduced kidney function.
• Hepatic dysfunction: evaluate liver function tests before initiation and monitor periodically.
• Infection monitoring: watch for signs of infection due to neutropenia and advise prompt medical attention.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: may reduce plasma concentrations of lenalidomide.
• Anticoagulants (warfarin, DOACs): increased bleeding risk; close INR monitoring required.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.
• Vaccines: live attenuated vaccines should be avoided due to altered immune response.
• CYP1A2 inhibitors: potential modest increase in drug exposure.
• NSAIDs: may exacerbate thrombocytopenia or renal effects.